期刊文献+

阿司匹林在脑卒中一级预防中的应用 被引量:4

Application of aspirin in the primary prevention of stroke
下载PDF
导出
摘要 阿司匹林对脑卒中二级预防的效果已经确定,但其在脑卒中一级预防中的获益和风险仍存在较大争议。基于现有的临床证据,仅部分人群从阿司匹林一级预防措施中获益,本文结合相关脑卒中一级预防指南和主要文献,就阿司匹林在脑卒中一级预防中的应用依据、作用机制、适用人群及风险评价等简要概述。 Aspirin is effective in the second prevention for stroke. However, its benefits and risk in the primary prevention are disputed. Based on current clinical observation, only part of the population could benefit from aspirin in the primary prevention. This article focuses on the evidence, mechanism, applicable people and risk assessment in the application of aspirin based on guidelines and important articles for the primary prevention of stroke.
作者 杨钊 刘建荣
出处 《中国现代神经疾病杂志》 CAS 2015年第2期103-108,共6页 Chinese Journal of Contemporary Neurology and Neurosurgery
关键词 卒中 一级预防 阿司匹林 综述 Stroke Primary prevention Aspirin Review
  • 相关文献

参考文献37

  • 1Peto R, Gray R, Collins R, Wheatley K, Hennekens C,Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S,Gilliland J, Doll R. Randomised trial of prophylactic dailyaspirin in British male doctors. Br Med J (Clin Res Ed), 1988,296:313-316.
  • 2Steering Committee of the Physicians" Health Study ResearchGroup. Final report on the aspirin component of the ongoingPhysicians Health Study. N Engl J Med, 1989, 321:129-135.
  • 3Medical Research Council's General Practice ResearchFramework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirinin the primary prevention of ischemic heart disease in men atincreased risk. Lancet, 1998, 351:233-241.
  • 4Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D,Julius S, Menard J, Rahn KH, Wedel H, Westerling S; HOTStudy Group. Effects of intensive blood - pressure lowering andlow-dose aspirin in patients with hypertension: principal resultsof the Hypertension Optimal Treatment (HOT) randomized trial.Lancet, 1998, 351:1755-1762.
  • 5de Gaetano G; Collaborative Group of the Primary PreventionProject. Low - dose aspirin and vitamin E in people atcardiovascular risk: a randomised trial in general practice.Lancet, 2001, 357:89-95.
  • 6Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, MansonJE, Hennekens CH,Buring JE. A randomized trial of low-doseaspirin in the primary prevention of cardiovascular disease inwomen. N Engl J Med, 2005, 352:1293-1304.
  • 7Bartolucci AA, Howard G. Meta - analysis of data from the sixprimary prevention trials of cardiovascular events using aspirin.Am J Cardiol, 2006,98:746-750.
  • 8Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M,Doi N,Jinnouchi H, Sugiyama S, Saito Y; Japanese PrimaryPrevention of Atherosclerosis With Aspirin for Diabetes (JPAD)Trial Investigators. Low-dose aspirin for primary prevention ofatherosclerotic events in patients with type 2 diabetes: arandomized controlled trial. JAMA, 2008, 300:2134-2141.
  • 9Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, PrescottR,Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P,Morris A, Jung R,Kelly C, Connacher A, Peden N, Jamieson A,Matthews D, Leese G, McKnight J, O'Brien I, Semple C, PetrieJ, Gordon D, Pringle S, MacWalter R; Prevention of Progressionof Arterial Disease and Diabetes Study Group; DiabetesRegistry Group; Royal College of Physicians Edinburgh. Theprevention of progression of arterial disease and diabetes(POPADAD) trial: factorial randomised placebo controlled trialof aspirin and antioxidants in patients with diabetes andasymptomatic peripheral arterial disease. BMJ, 2008, 337:A1840.
  • 10Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, PellAC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirinfor Asymptomatic Atherosclerosis Trialists. Aspirin forprevention of cardiovascular events in a general populationscreened for a low ankle brachial index: a randomizedcontrolled trial. JAMA, 2010,303:841-848.

二级参考文献36

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1401
  • 2张学义,张薇,郑兆通,钟明,黎莉,张运.非瓣膜性心房颤动并发缺血性脑卒中的防治[J].中华急诊医学杂志,2004,13(9):592-594. 被引量:21
  • 3Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 2005,353 : 2373-2383.
  • 4Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol,2006 ,98 :746-750.
  • 5Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol,2009 ,54 :2129-2138.
  • 6Chiang N, Serhan CN. Aspirin triggers formation of anti- inflammatory mediators: New mechanism for an old drug. Discov Med, 2004,4:470-475.
  • 7May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol,2008,28:s5-10.
  • 8Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost, 2008,99:480-486.
  • 9Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev, 2004, 84 : 1381-1478.
  • 10Oberle S, Polte T, Abate A, et al. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res, 1998,82 : 1016-1020.

共引文献224

同被引文献36

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部